Cosmo Pharmaceuticals NV (XSWX:COPN)
CHF 71 -1 (-1.39%) Market Cap: 1.14 Bil Enterprise Value: 1.09 Bil PE Ratio: 0 PB Ratio: 2.86 GF Score: 68/100

Cosmo Pharmaceuticals NV R&D Day Transcript

May 08, 2019 / 01:00PM GMT
Release Date Price: CHF101.6 (+2.63%)
Mauro Severino Ajani
Cosmo Pharmaceuticals N.V. - Founder & Chairman

First of all, thank you, and welcome to be here. This is a very important day. I know that every meeting starts with a very important day but this -- believe me this the truth that it is very important for the company. Let me spend some minutes just to remember when we started and where we are now and where we are going. Alessandro and the other team will tell you later.

So we started exactly 22 years ago and we listed the company in 2007. Since the beginning, the interest, my personal interest was not to develop a [B2] company, but we want something that must be new in terms of concept, in terms of approach, in terms of everything. And when developing out the first technology that is MMX, I remember that a lot of people at the time were advising me, they tried to push me and the company, the drug delivery segment. But I was not really convinced because for me, it was more important to try to develop a specialty pharma. And using the technology, we decided to enter in the colon area just because I realize that the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot